The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

KITCHENER, ON / ACCESSWIRE / September 27, 2024 / FemTech startup Hyivy Health has raised $2 million in their latest seed funding round from private investors to advance the Hyivy Pelvic Health ...

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Canada Royal Milk today celebrated the official grand opening of its infant formula manufacturing facility, marking the milestone occasion with community, regional and federal partners. "Seven years ...

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that additional data from ...

The Point-of-Care Diagnostics market is driven by the increasing demand for rapid and accurate testing solutions, particularly in remote and resource-limited settings. Technological advancements, such ...